How much does biotech IPO D&O insurance cost?

Biotech IPO D&O insurance carries the highest D&O premium of any sector and any stage. Typical placement for a clinical-stage biotech filing in the $200 million to $500 million market cap range runs $300,000 to $1.5 million for the first $10 million to $25 million of coverage, plus excess layers stacked above to a $50 million to $100 million total tower.

The cost drivers are (1) trial stage at IPO - Phase 1/2 readouts carry materially more securities class action risk than later-stage assets, (2) IPO/SPAC litigation experience in the comparable cohort over the prior 24 months, (3) deal size relative to projected revenue, (4) named-executive disclosure profile, and (5) any recent SEC enforcement adjacency. A biotech with a recent FDA hold or a sponsor MSA breach has a materially harder placement.

The structural decision is run-off (tail) coverage for the pre-IPO program. The board must continue to be protected for pre-IPO acts even after going public; standard practice is a 6-year run-off of the prior policy at typically 200-250% of the expiring premium. This is non-negotiable and routinely missed by management teams focused on the forward-going program.